Dongguk Pharmaceutical Achieves Record Results Last Year with Sales of KRW 926.9 Billion and Operating Profit of KRW 96.6 Billion

Sales Up 14.1%, Operating Profit Up 20.1%

Dongguk Pharmaceutical achieved its highest-ever performance last year, posting double-digit growth rates in both sales and operating profit.

According to a disclosure by Dongguk Pharmaceutical on March 5, the company recorded consolidated annual sales of KRW 926.9 billion and operating profit of KRW 96.6 billion last year. This represents an increase of 14.1% and 20.1%, respectively, compared to the previous year. Notably, fourth-quarter operating profit surged by 37.6% year-on-year, demonstrating strong growth momentum.

The exterior view of Dongkook Pharmaceutical Cheongdam Building in Gangnam-gu, Seoul. Dongkook Pharmaceutical

This robust performance is attributed to improved efficiency in selling and administrative expenses driven by increased sales, as well as diversification of distribution channels in the healthcare business, which led to enhanced profitability. All business divisions—including OTC (over-the-counter drugs), ETC (ethical drugs), healthcare, and global business—showed balanced growth.

The ethical drugs (ETC) segment recorded growth in the double digits compared to the previous year. In particular, company-produced injectable drugs stood out, with 'Lorelina'—a treatment for prostate cancer and precocious puberty—driving growth, and 'Allostin' significantly expanding its market share in the general hospital segment. In the healthcare division, the dermacosmetic brand 'Centellian24' achieved visible results in global markets such as North America and Japan, while the health functional food brand 'Myfit' series surpassed cumulative sales of KRW 38 billion, emerging as a core brand within the division.

Going forward, Dongguk Pharmaceutical plans to secure future pipelines and reinforce continuous growth engines through open innovation. In particular, the company aims to sequentially commercialize antifungal agent 'Amphotericin B,' based on liposome technology, and 'Lorelina,' utilizing microsphere technology, centering on the DK Pharmaceutical Research Institute, a dedicated drug delivery system (DDS) organization. Based on this, the company intends to develop various new products, including obesity treatments, and position itself as a global innovator in DDS.

This year, Dongguk Pharmaceutical plans to drive high growth of the newly launched pharmacy cosmetics brand 'Madeca Pharmacia,' while also expanding into the pet products segment as a new business. In addition, the company will continue its growth by expanding partnerships with other companies' products, leveraging its strong pharmacy distribution network. In the export sector, Dongguk Pharmaceutical intends to accelerate its push into global markets such as Turkey, Brazil, and Mexico, focusing on high value-added products such as the benign prostatic hyperplasia combination drug 'Uresco.'

This content was produced with the assistance of AI translation services.